08.08.24 -- The Future Of IRBs: Embracing Tech To Enhance Patient Safety, Research Efficiency

Better understand how smaller biotech companies should approach CRO selection and what they should consider before launching their clinical development program.

Join our panel of experts for an in-depth review of the FDA's guidance on psychedelic drug development, exploring necessary methodological adaptations for safety, pharmacology, and efficacy.

With a proven track record built on decades of experience, we provide the talent and expertise to help our clients meet their timelines with much-needed resource flexibility, reliability, and continuity.

Experience automated patient information flow from IRT to eCOA, reducing errors and investigator burden. Kayentis Clin’form stands ready for integration, simplifying your trial processes.

If you are unsure of how to navigate your post-approval regulatory journey, an experienced regulatory services partner can provide support to help you identify and achieve post-approval goals.

By listening to the voice of patient diversity and implementing FDA guidance measures, learn how stakeholders can improve trust, engagement, data reliability, patient outcomes, and more.

Explore several modifications introduced in the updated guidelines by the European Medicines Agency regarding computerized systems and electronic data in clinical trials.

Get support for post-authorization regulatory requirements, spanning product launches, management of variations, new indications, line extensions, and ensuring ongoing compliance.